Pharmaceuticals (Feb 2021)

Discovery and Optimization of Selective Inhibitors of Meprin α (Part I)

  • Shurong Hou,
  • Juan Diez,
  • Chao Wang,
  • Christoph Becker-Pauly,
  • Gregg B. Fields,
  • Thomas Bannister,
  • Timothy P. Spicer,
  • Louis D. Scampavia,
  • Dmitriy Minond

DOI
https://doi.org/10.3390/ph14030203
Journal volume & issue
Vol. 14, no. 3
p. 203

Abstract

Read online

Meprin α and β are zinc-dependent proteinases implicated in multiple diseases including cancers, fibrosis, and Alzheimer’s. However, until recently, only a few inhibitors of either meprin were reported and no inhibitors are in preclinical development. Moreover, inhibitors of other metzincins developed in previous years are not effective in inhibiting meprins suggesting the need for de novo discovery effort. To address the paucity of tractable meprin inhibitors we developed ultrahigh-throughput assays and conducted parallel screening of >650,000 compounds against each meprin. As a result of this effort, we identified five selective meprin α hits belonging to three different chemotypes (triazole-hydroxyacetamides, sulfonamide-hydroxypropanamides, and phenoxy-hydroxyacetamides). These hits demonstrated a nanomolar to micromolar inhibitory activity against meprin α with low cytotoxicity and >30-fold selectivity against meprin β and other related metzincincs. These selective inhibitors of meprin α provide a good starting point for further optimization.

Keywords